{"id":49755,"date":"2025-12-02T20:37:35","date_gmt":"2025-12-02T12:37:35","guid":{"rendered":"https:\/\/flcube.com\/?p=49755"},"modified":"2025-12-02T20:37:36","modified_gmt":"2025-12-02T12:37:36","slug":"canbridges-maralixibat-wins-hong-kong-approval-for-pfic-cholestatic-pruritus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49755","title":{"rendered":"CANbridge&#8217;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus"},"content":{"rendered":"\n<p><strong>CANbridge Pharmaceuticals Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1228:HKG\">HKG: 1228<\/a>) announced that <strong>maralixibat<\/strong> has been approved by the <strong>Department of Health of Hong Kong, China<\/strong> for the treatment of <strong>cholestatic pruritus<\/strong> in patients aged <strong>3 months and above<\/strong> with <strong>progressive familial intrahepatic cholestasis (PFIC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-indication\">Regulatory Milestone &amp; Indication<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>maralixibat<\/td><\/tr><tr><td><strong>Approval Authority<\/strong><\/td><td>Department of Health, Hong Kong SAR<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cholestatic pruritus in PFIC patients<\/td><\/tr><tr><td><strong>Age Eligibility<\/strong><\/td><td>\u22653 months<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First PFIC approval for CANbridge in Hong Kong; expands Greater China footprint<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-origin-amp-mechanism-of-action\">Drug Origin &amp; Mechanism of Action<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Original Discovery<\/strong><\/td><td>Mirum Pharmaceuticals (US)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>IBAT (Ileal Bile Acid Transporter) inhibitor<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks enterohepatic circulation of bile acids, reducing liver\/serum bile acid levels and relieving pruritus<\/td><\/tr><tr><td><strong>US Trade Name<\/strong><\/td><td>Livmarli\u00ae<\/td><\/tr><tr><td><strong>US FDA Approvals<\/strong><\/td><td>ALGS (Sept\u202f2021, age \u22651 year); PFIC (age \u226512 months)<\/td><\/tr><tr><td><strong>China Approval<\/strong><\/td><td>ALGS (June\u202f2023, age \u22651 year)<\/td><\/tr><tr><td><strong>Licensing<\/strong><\/td><td>Exclusive Greater China rights secured by CANbridge (April\u202f2021)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PFIC Prevalence<\/strong>: Rare pediatric cholestatic disease affecting ~1-2 per 100,000 births; significant unmet need in Asia.<\/li>\n\n\n\n<li><strong>Hong Kong Market<\/strong>: Local approval enables market access and reimbursement pathways within the Greater China region.<\/li>\n\n\n\n<li><strong>Competitive Position<\/strong>: No other IBAT inhibitors approved for PFIC in Hong Kong; Livmarli is established standard-of-care in US\/EU.<\/li>\n\n\n\n<li><strong>CANbridge Strategy<\/strong>: Builds on rare disease leadership; leverages existing ALGS infrastructure for PFIC launch.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-financial-implications\">Strategic Outlook &amp; Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Model<\/strong>: Rare disease pricing expected at <strong>US$200,000-300,000<\/strong> annual cost per patient; Hong Kong market potential estimated at <strong>US$5-10\u202fmillion<\/strong> peak sales.<\/li>\n\n\n\n<li><strong>Next Steps<\/strong>: CANbridge will pursue reimbursement listing in Hong Kong Hospital Authority; potential expansion to <strong>Macau<\/strong> and <strong>Taiwan<\/strong>.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong>: PFIC approval strengthens CANbridge\u2019s pediatric liver disease franchise alongside ALGS; may enable lifecycle management for next-generation IBAT programs.<\/li>\n\n\n\n<li><strong>Investor Value<\/strong>: Approval triggers milestone payment to Mirum; demonstrates CANbridge\u2019s execution capability in licensed assets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding maralixibat\u2019s commercial launch timeline, reimbursement outcomes, and market penetration in Hong Kong. Actual results may differ due to regulatory, pricing, and competitive risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49757,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[142,883,15],"class_list":["post-49755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-canbridge-pharmaceuticals","tag-hkg-1228","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CANbridge&#039;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49755\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CANbridge&#039;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus\" \/>\n<meta property=\"og:description\" content=\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49755\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T12:37:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T12:37:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CANbridge&#8217;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus\",\"datePublished\":\"2025-12-02T12:37:35+00:00\",\"dateModified\":\"2025-12-02T12:37:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0202-1.webp\",\"keywords\":[\"CANbridge Pharmaceuticals\",\"HKG: 1228\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49755#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49755\",\"name\":\"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0202-1.webp\",\"datePublished\":\"2025-12-02T12:37:35+00:00\",\"dateModified\":\"2025-12-02T12:37:36+00:00\",\"description\":\"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49755\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0202-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0202-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49755#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CANbridge&#8217;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus - Insight, China&#039;s Pharmaceutical Industry","description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49755","og_locale":"en_US","og_type":"article","og_title":"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus","og_description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).","og_url":"https:\/\/flcube.com\/?p=49755","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-02T12:37:35+00:00","article_modified_time":"2025-12-02T12:37:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49755#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49755"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CANbridge&#8217;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus","datePublished":"2025-12-02T12:37:35+00:00","dateModified":"2025-12-02T12:37:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49755"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49755#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","keywords":["CANbridge Pharmaceuticals","HKG: 1228","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49755#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49755","url":"https:\/\/flcube.com\/?p=49755","name":"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49755#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49755#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","datePublished":"2025-12-02T12:37:35+00:00","dateModified":"2025-12-02T12:37:36+00:00","description":"CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of Health of Hong Kong, China for the treatment of cholestatic pruritus in patients aged 3 months and above with progressive familial intrahepatic cholestasis (PFIC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49755#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49755"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49755#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","width":1080,"height":608,"caption":"CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49755#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CANbridge&#8217;s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0202-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49755"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49755\/revisions"}],"predecessor-version":[{"id":49758,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49755\/revisions\/49758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49757"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}